Fractional Microneedle Radiofrequency Combined Dihydromyricetin Photoaging Fractional Microneedle Radiofrequency Combined Dihydromyricetin Photoaging
Conditions
Interventions
Participants in this group will receive non-insulated fractional microneedle radiofrequency treatment at standardized parameters Immediately following each FMR session, a topical DHM-based cream will
Experimental Device,Placebo Comparator Device
Fractional Microneedle Radiofrequency Combined with Topical Dihydromyricetin,Fractional Microneedle Radiofrequency Combined with Topical placebo cream
Sponsors
None listed
Eligibility
Sex/Gender
All
Age
20 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Adults aged 20 to70 years, of either sex. 2. Clinically diagnosed by a dermatologist with facial melasma involving both sides of the face, with no requirement to specify lesion size, and willing to refrain from using any other facial skincare or cosmetic treatments during the study period, including botulinum toxin injections, dermal fillers, laser treatments, thread lifting, or dermabrasion. 3. Able to comply with all study procedures, attend scheduled follow-up visits throughout the study period, and promptly report any adverse events related to the study.
Exclusion criteria
Exclusion criteria: 1. History of systemic retinoid (acitretin, isotretinoin), methotrexate, photosensitizing or phototoxic drugs, tranexamic acid, glutathione, or vitamin supplements (A, B, etc.) use within 6 months prior to study initiation. 2. History of microdermabrasion, IPL, pigment laser treatments, ablative or non-ablative resurfacing lasers, chemical peels, botulinum toxin, or dermal filler injections on the face within 6 months prior to the study. 3. Use of topical medications for melasma within 1 month before study enrollment. 4. Presence of photosensitive dermatoses, infectious or inflammatory skin diseases, or inflammatory acne in the treatment area. 5. Personal or family history of skin cancer. 6. History of herpes simplex infection on the face. 7. History of hypertrophic scars or keloids. 8. Presence of serious chronic illnesses requiring continuous treatment, such as cirrhosis, chronic renal failure, malignancy, or immunodeficiency disorders. 9. Current use of anticoagulant medications. 10. Pregnant or breastfeeding women, or those planning pregnancy or not using contraception. 11. Current smokers or individuals who smoke regularly. 12. Inability to attend treatment sessions or follow-up visits according to the study schedule. 13. History of allergy to local anesthetics.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| efficacy 0,2,4,6,8,10,18 week modified melasma area severity index | — |
Secondary
| Measure | Time frame |
|---|---|
| Melanin average level,vessel density measurement, 0,8,10,18 week antera camera, optical coherence tomography ,melanin pigment, collagen in dermis, thickness of basement membrane 0,10 week histological analysis(Fontana Masson stain ,Masson trichrome ,Periodic acid-Schiff stain ),side effect of Fractional Microneedle Radiofrequency Combined with Topical Dihydromyricetin compare with Fractional Microneedle Radiofrequency Combined with Topical Placebo cream 0,2,4,6,10,18 week questionnaire,Satisfaction questionnaire 18th week 9-point rating scale | — |
Countries
Thailand
Contacts
Public ContactWareeporn Disphanurat
Thammasat university hospital
Outcome results
None listed